Interval to Biochemical Failure Highly Prognostic for Distant Metastasis and Prostate Cancer-Specific Mortality After Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 1, 2008, Pages 59-66

  Buyyounouski, Mark K ^a   Hanlon, Alexandra L ^a   Horwitz, Eric M ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Prognostic factor; Prostate cancer; Prostate specific antigen; Radiotherapy; Treatment failure

Indexed keywords

ANTIGENS; BIOCHEMICAL ENGINEERING; BIOMATERIALS; ONCOLOGY; RADIOTHERAPY;

INTERVAL TO BIOCHEMICAL FAILURE (IBF); PROGNOSTIC FACTOR; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGENS; TREATMENT FAILURE;

FAILURE ANALYSIS;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DISTANT METASTASIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TIME FACTORS; TREATMENT FAILURE;

EID: 37049031020     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.047     Document Type: Article

References (29)

1. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
2. Pickles T., Kim-Sing C., Morris W.J., et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57 (2003) 11-18
3. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
4. Vicini F.A., Kestin L.L., and Martinez A.A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 88 (2000) 2305-2318
5. Kestin L.L., Vicini F.A., and Martinez A.A. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 53 (2002) 304-315
6. Buyyounouski M.K., Hanlon A.L., Eisenberg D.F., et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1455-1462
7. Cox G., Kaplan G., and American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
8. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
9. DeWitt K.D., Sandler H.M., Weinberg V., et al. What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?. Urology 62 (2003) 492-496
10. Crook J.M., Bahadur Y.A., Bociek R.G., et al. Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79 (1997) 328-336
11. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 36 (1996) 565-571
12. Lee W.R., Hanlon A.L., and Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival. J Urol 156 (1996) 450-453
13. Ray M.E., Thames H.D., Levy L.B., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 64 (2006) 1140-1150
14. Kestin L.L., Vicini F.A., Ziaja E.L., et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 86 (1999) 1557-1566
15. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S47
16. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
17. American Joint Committee on Cancer. Prostate. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual (2002), Springer, New York 337-345
18. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 92 (2001) 1281-1287
19. Monti A.F., Ostinelli A., Frigerio M., et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol 35 (1995) 145-150
20. Chism D.B., Hanlon A.L., Horwitz E.M., et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 380-385
21. Coen J.J., Chung C.S., Shipley W.U., et al. Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: Results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys 57 (2003) 621-628
22. Zietman A.L., Christodouleas J.P., and Shipley W.U. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: Impact on definitions of failure. Int J Radiat Oncol Biol Phys 62 (2005) 714-718
23. Horwitz E.M., Thames H.D., Kuban D.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173 (2005) 797-802
24. Buyyounouski M.K., Hanlon A.L., and Pollack A. The temporal kinetics of PSA after 3D-conformal radiotherapy with androgen deprivation. Int J Radiat Oncol Biol Phys 61 (2005) 1291-1298
25. Kestin L.L., Vicini F.A., and Martinez A.A. Potential survival advantage with early androgen deprivation for biochemical failure after external beam radiotherapy: The importance of accurately defining biochemical disease status. Int J Radiat Oncol Biol Phys 60 (2004) 453-462
26. Lin D.D., Schultz D., Renshaw A.A., et al. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology 65 (2005) 528-532
27. Valicenti R.K., Desilvio M., Hanks G.E., et al. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group protocol 92-02. Int J Radiat Oncol Biol Phys 66 (2006) 1064-1071
28. Hanlon A.L., Horwitz E.M., Hanks G.E., et al. Short-term androgen deprivation and PSA doubling time: Their association and relationship to disease progression after radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 43-52
29. Lee A.K., Levy L.B., Cheung R., et al. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63 (2005) 456-462